Protein Sciences Corp., of Meriden, Conn.; UNM Pharma Inc., of Akita, Japan; and IHI Corp., of Tokyo, said they entered an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu (Japan) plant of Unigen, a subsidiary of UMN Pharma in which IHI holds 50 percent of the common shares. Read More
BioWorld's offices will be closed Thursday, Dec. 25, in observance of the Christmas Day holiday in the U.S. No issues will be published those days. Read More
SHANGHAI – China has announced that it will be initiating phase I trials for Ad5-Ebov, a recombinant adenoviral Ebola vaccine co-developed by the Bioengineering Institute of the Chinese Academy of Military Medical Sciences (AMMS) and vaccine start-up Tianjin Cansino Biotechnology Inc. Read More
HONG KONG – Research into the different mechanisms contributing to the development of antibiotic resistance may lead not only to the discovery of new methods for preventing the acquisition of microbial resistance, but also potentially may result in the development of new antibiotics, according to Japanese scientists Read More
NEW DELHI – India's Supreme Court has dismissed German multinational Bayer AG's appeal against attempts to make and sell cheaper generic versions of its cancer drug, Nexavar (sorafenib tosylate), used to treat liver and rectal cancers. Read More
TOKYO – Japan, with the world's third-highest rate of stomach cancer behind Mongolia and the Republic of Korea, will soon have another combination drug mix to help treat the disease. Read More
SHANGHAI – Sciclone Pharmaceuticals Inc. has had a pretty good year. The company continues to grow in the double digits and has hit revenue expectations for several quarters, helping to push stock prices to a rosy $8 to $9 range from a depressed low of $4 last year. It has shown that it can ride out the end of a significant commercial contract with Sanofi SA without much damage, as well as live with the reality of a seemingly never-ending SEC investigation. Read More
